Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients

Misiak, Błażej; Frydecka, Dorota; Łaczmański, Łukasz; Ślężak, Ryszard; Kiejna, Andrzej

doi:10.1007/s00228-014-1762-2

Cited by 31 publications

(28 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The reason behind this is mentally ill condition itself and medications. There is a considerable literature on the metabolic adverse effects of antipsychotic agents and, in particular, second generation antipsychotics (SGAs) appear to induce more weight gain and metabolic abnormalities than first generation antipsychotics (FGAs) [8]. However, in this study metabolic syndrome is more prevalence among trifluoperazine (70%) drug group than risperidone (66.6%) and olanzapine (53.12%).…”

Section: Discussioncontrasting

confidence: 49%

Metabolic Syndrome, and Cardiovascular Risk among Mentally Ill Patients

Umakanth¹,

Gadambanathan²

2018

JBM

View full text Add to dashboard Cite

Patients with serious mental illness have an increased prevalence of the metabolic syndrome in comparison to the general population. Metabolic syndrome is a constellation of cardiovascular risk factors including diabetes, hypertension, obesity and dyslipidemia. It is potentially reversible and may explain the higher incidence of cardiovascular disease in patients with serious mental illness. The aim of the study is to see the prevalence of metabolic syndrome among mentally ill patients and what might be the underlying the cause behind the scene A descriptive, retrospective study was conducted at mental health clinic, Batticaloa, Teaching Hospital (BTH), Sri Lanka. The data were collected over a period of two months from 15th of October to 15th of December 2017. Data were harvested from the medical records. Total 55 mentally ill patient's medical records were analyzed for this study. Out of 55, females were 30 (54.5%) and males were 25 (45.5%). Furthermore, 30 (54.5%) patients had an evidence of metabolic syndrome. The association of metabolic syndrome among male and female was not statistically significant (P > 0.05). In this study, metabolic syndrome is more prevalent among, patient with trifluoperazine (70%) drug group, risperidone (66.6%) and olanzapine (53.12%).

show abstract

Section: Discussioncontrasting

confidence: 49%

Metabolic Syndrome, and Cardiovascular Risk among Mentally Ill Patients

Umakanth¹,

Gadambanathan²

2018

JBM

View full text Add to dashboard Cite

show abstract

“…It will also be necessary to have studies adequately powered to allow for further group separation by sex because research in 2014 showed this to be an important factor in determining changes in folate cycle metabolites following antipsychotic administration. 42 Despite these intriguing findings, we acknowledge that this was an exploratory study with several limitations. First, this was a retrospective investigation that used existing blood samples from a relatively small sample size, preventing us from drawing conclusions about AAP-induced changes on the metabolome.…”

Section: Discussionmentioning

confidence: 89%

“…In the future, it will be important to capture changes in the metabolome before and for an extended period of time after AAP initiation and medication switches. It will also be necessary to have studies adequately powered to allow for further group separation by sex because research in 2014 showed this to be an important factor in determining changes in folate cycle metabolites following antipsychotic administration …”

Section: Discussionmentioning

confidence: 99%

Atypical Antipsychotic Exposure May Not Differentiate Metabolic Phenotypes of Patients with Schizophrenia

et al. 2018

View full text Add to dashboard Cite

Our results illustrate the utility of metabolomics to identify pathways underlying variable fasting insulin concentration in patients with schizophrenia. Importantly, no significant difference in AAP exposure was observed among groups, suggesting that current antipsychotic use may not be a primary factor that differentiates middle-aged adult patients with schizophrenia by fasting insulin concentration.

show abstract

“…Èçìåíåíèÿ â óðîâíÿõ ãîìîöèñòåèíà áûëè àññîöèèðîâàíû ñ ïîëîì è îñíîâíûìè ìåòàáîëè÷åñêèìè ïàðàìåòðàìè (èíäåêñ ìàññû òåëà, ãëþêîçà, òðèãëèöåðèäû è äðóãèå ïîêàçàòåëè) ó áîëüíûõ øèçîôðåíèåé ñ ïåðâûì ýïèçîäîì, ïîëó÷àþùèõ ìîíîòåðàïèþ àòèïè÷íûìè íåéðîëåïòèêàìè (îëàíçàïèíîì èëè ðèñïèðèäîíîì) [50].…”

Section: аминокислоты как маркеры терапевтического ответа на антипсихunclassified

Amino acids and acylcarnitines as potential metabolomic markers of schizophrenia: new approaches to diagnostics and therapy

et al. 2020

View full text Add to dashboard Cite

Background. Schizophrenia is a socially significant mental illness with insufficiently studied etiology and pathogenesis. A number of hypotheses of schizophrenia pathogenesis (dopamine, glutamate, kinurenin and serotonin hypotheses) bring together the fact that amino acids are precursors or intermediate metabolic products of these metabolites. Amino acids and their metabolites play an important role as significant substrates and regulators in many metabolic pathways.The aim of this review is to analyze the literature data on the studies of amino acids and acylcarnitines in patients with schizophrenia.Methods. A literature search was conducted using PubMed databases for articles published in English and covering the period from the first articles on this topic, dated 1977 to April 2019. Combinations of the following keywords were used to search for “schizophrenia”, “antipsychotics” and “amino acids”, “acylcarnitines”, “metabolomics”.Results. The review summarizes the data on the content of amino acids and acylcarnitines in the peripheral blood of schizophrenia patients and their dynamics in the course of pharmacotherapy with antipsychotic drugs. The potential of determining amino acids as biomarkers of therapeutic response and side effects, as well as their use in the treatment of patients with schizophrenia, are considered.Conclusion. Further investigation of the spectrum of amino acids and their metabolites with the using of mass spectrometric methods of metabolic analysis can lead to the discovery of new therapeutic targets and strategies, assess their role in the pathophysiology of schizophrenia, identify mechanisms that ensure the development of antipsychotic antipsychotics, and drug-induced side effects antipsychotics, in particular, metabolic syndrome.

show abstract

Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients

Cited by 31 publications

References 55 publications

Metabolic Syndrome, and Cardiovascular Risk among Mentally Ill Patients

Metabolic Syndrome, and Cardiovascular Risk among Mentally Ill Patients

Atypical Antipsychotic Exposure May Not Differentiate Metabolic Phenotypes of Patients with Schizophrenia

Amino acids and acylcarnitines as potential metabolomic markers of schizophrenia: new approaches to diagnostics and therapy

Contact Info

Product

Resources

About